These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis. Ferreira T; Kulkarni A; Bretscher C; Richter K; Ehrlich M; Marchini A Viruses; 2020 Oct; 12(10):. PubMed ID: 33096814 [TBL] [Abstract][Full Text] [Related]
7. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1. Moehler M; Sieben M; Roth S; Springsguth F; Leuchs B; Zeidler M; Dinsart C; Rommelaere J; Galle PR BMC Cancer; 2011 Oct; 11():464. PubMed ID: 22029859 [TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic Vascular Endothelial Growth Factor-Blocking Peptides Displayed on the Capsid of an Infectious Oncolytic Parvovirus: Assembly and Immune Interactions. Grueso E; Sánchez-Martínez C; Calvo-López T; de Miguel FJ; Blanco-Menéndez N; Fernandez-Estevez M; Elizalde M; Sanchez J; Kourani O; Martin D; Tato A; Guerra M; Andrés G; Almendral JM J Virol; 2019 Oct; 93(19):. PubMed ID: 31315994 [TBL] [Abstract][Full Text] [Related]
9. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future. Bretscher C; Marchini A Viruses; 2019 Jun; 11(6):. PubMed ID: 31216641 [TBL] [Abstract][Full Text] [Related]
10. Parvovirus Capsid Structures Required for Infection: Mutations Controlling Receptor Recognition and Protease Cleavages. Callaway HM; Feng KH; Lee DW; Allison AB; Pinard M; McKenna R; Agbandje-McKenna M; Hafenstein S; Parrish CR J Virol; 2017 Jan; 91(2):. PubMed ID: 27847360 [TBL] [Abstract][Full Text] [Related]
11. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo. Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280 [TBL] [Abstract][Full Text] [Related]
12. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies. Angelova AL; Aprahamian M; Balboni G; Delecluse HJ; Feederle R; Kiprianova I; Grekova SP; Galabov AS; Witzens-Harig M; Ho AD; Rommelaere J; Raykov Z Mol Ther; 2009 Jul; 17(7):1164-72. PubMed ID: 19367260 [TBL] [Abstract][Full Text] [Related]
17. Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas. Li J; Bonifati S; Hristov G; Marttila T; Valmary-Degano S; Stanzel S; Schnölzer M; Mougin C; Aprahamian M; Grekova SP; Raykov Z; Rommelaere J; Marchini A EMBO Mol Med; 2013 Oct; 5(10):1537-55. PubMed ID: 24092664 [TBL] [Abstract][Full Text] [Related]
18. Regression of glioma in rat models by intranasal application of parvovirus h-1. Kiprianova I; Thomas N; Ayache A; Fischer M; Leuchs B; Klein M; Rommelaere J; Schlehofer JR Clin Cancer Res; 2011 Aug; 17(16):5333-42. PubMed ID: 21715567 [TBL] [Abstract][Full Text] [Related]
19. Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells. Lacroix J; Leuchs B; Li J; Hristov G; Deubzer HE; Kulozik AE; Rommelaere J; Schlehofer JR; Witt O Int J Cancer; 2010 Sep; 127(5):1230-9. PubMed ID: 20087864 [TBL] [Abstract][Full Text] [Related]
20. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection. Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR J Biomed Biotechnol; 2010; 2010():350748. PubMed ID: 20224643 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]